Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve.
CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people.
We are leveraging a deep understanding of validated human biology coupled with a brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. Our pipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder.
CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people.
We are leveraging a deep understanding of validated human biology coupled with a brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. Our pipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $176M
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | S32 | s32.com |
| - | Section 32 | section32.... |
| 08.08.2024 | Newpath Ma... | newpath.pa... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.07.2024 | Series C | $100M | - |
| 11.06.2020 | Series B | $76M | - |
Mentions in press and media 8
| Date | Title | Description |
| 30.07.2024 | The New Frontier in Biotech: Partnerships and Innovations Shaping the Future of Medicine | In the ever-evolving landscape of biotechnology, partnerships are the lifeblood of innovation. Two recent collaborations highlight this trend: GSK's partnership with Flagship Pioneering and Autobahn Therapeutics' successful funding round. B... |
| 29.07.2024 | Autobahn Therapeutics: $100 Million Raised To Develop Restorative Treatments For Depression and Other CNS Disorders | Autobahn Therapeutics (a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders) announced the closing of an oversubscribed $100 million Series C funding led by Newpath... |
| 26.07.2024 | The Week’s 10 Biggest Funding Rounds: Space Tech Startup Astranis Tops List | 5 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w... |
| 25.07.2024 | Autobahn Therapeutics Completes $100M Series C Financing | Autobahn Therapeutics, a San Diego, CA-based biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, raised $100M in Series C funding. The round was led by Newpath Part... |
| 11.06.2020 | Autobahn Therapeutics Raises $76 Million To Develop Therapies For CNS Disorders | Autobahn Therapeutics announced it has completed a $76 million Series B fundraising co-led by ARCH Venture Partners and Cowen Healthcare Investments Autobahn Therapeutics announced it is launching to create the next-generation of regenerati... |
| 09.06.2020 | Autobahn Therapeutics Raises $76M in Series B Financing | Autobahn Therapeutics, a San Diego, CA-based developer of regenerative medicines to restore hope for people affected by CNS disorders, completed a $76m Series B funding round. The round was co-led by Arch Venture Partners and Cowen Healthca... |
| 09.06.2020 | Autobahn Therapeutics Takes Aim at CNS Disorders with $76 Million Series B | - |
| - | Autobahn Therapeutics | “Autobahn aims to improve life health for people affected by CNS disorders by driving the regenerative power of the human body.” |